ASN
NTLA icon

Advisory Services Network’s Intellia Therapeutics NTLA Stock Holding History

Advisory Services Network’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,575
Closed -$33K – 3797
2026
Q1 		$33K Buy
+2,575
New +$32.8K ﹤0.01% 2888
2025
Q4 		– Sell
-1,889
Closed -$32.6K – 3435
2025
Q3 		$32.6K Buy
+1,889
New +$23.3K ﹤0.01% 2711
2024
Q1 		– Sell
-1,577
Closed -$48.1K – 2898
2023
Q4 		$48.1K Buy
+1,577
New +$45.3K ﹤0.01% 2033
2023
Q2 		– Sell
-1,261
Closed -$47K – 2870
2023
Q1 		$47K Sell
1,261
-195
-13% -$7.65K ﹤0.01% 2055
2022
Q4 		$50.8K Buy
+1,456
New +$69.2K ﹤0.01% 1966
2021
Q3 		– Sell
-200
Closed -$32K – 2601
2021
Q2 		$32K Buy
+200
New +$15.6K ﹤0.01% 2236
2021
Q1 		– Sell
-300
Closed -$16K – 2403
2020
Q4 		$16K Buy
300
+292
+3,650% +$10.6K ﹤0.01% 2231
2020
Q3 		$0 Buy
+8
New +$167 ﹤0.01% 3613

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Advisory Services Network's NTLA Position: Q2 2026 in Review

Advisory Services Network sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 2,575 shares — an estimated $33K sold.

Advisory Services Network first reported a position in NTLA in Q3 2020 and held it in 8 quarters. The position peaked at $50.8K in Q4 2022. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Advisory Services Network reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Advisory Services Network sold 2,575 Intellia Therapeutics shares in Q2 2026, an estimated $33K.
  • Advisory Services Network first reported a position in Intellia Therapeutics in Q3 2020 and held it in 8 quarters.
  • Advisory Services Network's Intellia Therapeutics position peaked at $50.8K in Q4 2022.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.